The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14740%2F17%3A00098134" target="_blank" >RIV/00216224:14740/17:00098134 - isvavai.cz</a>
Result on the web
<a href="http://mct.aacrjournals.org/content/16/10_Supplement/A34" target="_blank" >http://mct.aacrjournals.org/content/16/10_Supplement/A34</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1538-8514.SYNTHLETH-A34" target="_blank" >10.1158/1538-8514.SYNTHLETH-A34</a>

Result language
angličtina
Original language name
The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
Original language description
It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.
Czech name
—
Czech description
—

Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)